O045 Participants with OSA severity improvement following treatment: SURMOUNT-OSA post-hoc analyses

Abstract Introduction In the SURMOUNT-OSA studies, tirzepatide reduced apnea-hypopnea index (AHI) values in participants living with moderate-to-severe OSA and obesity. The proportion of participants with improved obstructive sleep apnea (OSA) severity after tirzepatide treatment in these studies was investigated. Methods SURMOUNT-OSA included two studies: Study 1, consisting of participants not using positive airway pressure (PAP), and Study 2, consisting of participants using PAP. The efficacy analysis set included all randomized participants who received at least one dose of the study intervention, excluding data after treatment discontinuation. Participants were categorized at baseline and week-52 based on OSA severity using the AHI level. Categorical shifts in OSA severity from baseline to week-52 were evaluated and classified as improvement, worsening, or no change. Results In Study 1, a higher proportion of participants treated with tirzepatide showed improvement in their AHI category compared to the placebo group (67.7% vs. 26.8%). Similarly, in Study 2, a higher proportion of tirzepatide-treated participants showed improvement compared to the placebo group (79.0% vs. 25.3%). The percentage of participants treated with tirzepatide that achieved the no OSA present category was 24% in Study 1 and 36% in Study 2. Conclusion In these post-hoc analyses, tirzepatide treatment was associated with improvements in the severity of OSA from baseline to week-52 compared to placebo in adults with moderate-to-severe OSA and obesity. The majority of tirzepatide-treated participants shifted to an improved OSA category with 24-36% achieving no OSA present.